These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29740676)

  • 1. Adverse reactions associated with first-line regimens in patient initiating antiretroviral therapy.
    Mendes JC; Bonolo PF; Ceccato MDGB; Costa JO; Reis AMM; Dos Santos H; Silveira MR
    Eur J Clin Pharmacol; 2018 Aug; 74(8):1077-1088. PubMed ID: 29740676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection.
    Deng L; Li C; Chen P; Luo X; Zheng X; Zhou L; Zhou Y; Xia J; Hong Z
    BMC Infect Dis; 2022 Jan; 22(1):17. PubMed ID: 34983415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.
    Eluwa GI; Badru T; Agu KA; Akpoigbe KJ; Chabikuli O; Hamelmann C
    BMC Clin Pharmacol; 2012 Feb; 12():7. PubMed ID: 22369677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropsychiatric adverse drug reactions and associated factors in a cohort of individuals starting dolutegravir-based or efavirenz-based antiretroviral therapy in Belo Horizonte, Brazil.
    Mendes JC; Braga MDG; Reis AMM; Silveira MR
    Curr Med Res Opin; 2023 Apr; 39(4):523-531. PubMed ID: 36912019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
    Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
    PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study.
    Sawry S; Ayalew K; Maimela G; Briggs-Hagen M; van Wyk-Heath M; Mthethwa S; Shai S; Mngomezulu NN; Tlhowe L; Achere-Darko J; Bedford J; Martin CE; Fairlie L; Imrie J
    HIV Med; 2024 Jul; 25(7):826-839. PubMed ID: 38520085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
    Adedeji TA; Adebisi SA; Adedeji NO
    Infect Disord Drug Targets; 2020; 20(3):374-384. PubMed ID: 31389318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
    Rutherford GW; Horvath H
    PLoS One; 2016; 11(10):e0162775. PubMed ID: 27736859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
    Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
    Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?
    Vitoria M; Hill A; Ford N; Doherty M; Clayden P; Venter F; Ripin D; Flexner C; Domanico PL
    AIDS; 2018 Jul; 32(12):1551-1561. PubMed ID: 29746295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.
    Kanters S; Vitoria M; Doherty M; Socias ME; Ford N; Forrest JI; Popoff E; Bansback N; Nsanzimana S; Thorlund K; Mills EJ
    Lancet HIV; 2016 Nov; 3(11):e510-e520. PubMed ID: 27658869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse drug reactions of Highly Active Antiretroviral Therapy (HAART) in HIV infected patients at the General Hospital, Douala, Cameroon: a cross sectional study.
    Namme Luma H; Doualla MS; Choukem SP; Temfack E; Ashuntantang G; Achu Joko H; Koulla-Shiro S
    Pan Afr Med J; 2012; 12():87. PubMed ID: 23077708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
    Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
    N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dolutegravir in real life: Self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho.
    Brown JA; Nsakala BL; Mokhele K; Rakuoane I; Muhairwe J; Glass TR; Amstutz A; Tschumi N; Belus JM; Klimkait T; Labhardt ND
    HIV Med; 2023 Feb; 24(2):153-162. PubMed ID: 35730213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
    Santevecchi BA; Miller S; Childs-Kean LM
    Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events in Chinese human immunodeficiency virus (HIV) patients receiving first line antiretroviral therapy.
    Dai L; Su B; Liu A; Zhang H; Wu H; Zhang T; Shao Y; Li J; Ye J; Bai S; Guo X; Sun L
    BMC Infect Dis; 2020 Feb; 20(1):158. PubMed ID: 32075584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal trends and determinants of patient-reported side effects on ART-a Swedish national registry study.
    Mellgren Å; Eriksson LE; Reinius M; Marrone G; Svedhem V
    PLoS One; 2020; 15(12):e0242710. PubMed ID: 33362248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
    Greig SL; Deeks ED
    Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India.
    Zheng A; Kumarasamy N; Huang M; Paltiel AD; Mayer KH; Rewari BB; Walensky RP; Freedberg KA
    J Int AIDS Soc; 2018 Mar; 21(3):e25085. PubMed ID: 29603882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse drug reactions to integrase strand transfer inhibitors.
    Lepik KJ; Yip B; Ulloa AC; Wang L; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
    AIDS; 2018 Apr; 32(7):903-912. PubMed ID: 29424784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.